Jeffrey Eisele - 30 Jan 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Development Officer
Signature
/s/ David Watson, attorney-in-fact for Jeffrey Eisele
Issuer symbol
APLS
Transactions as of
30 Jan 2023
Transactions value $
-$46,587
Form type
4
Filing time
31 Jan 2023, 15:51:46 UTC
Previous filing
30 Jan 2023
Next filing
22 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Sale -$46,587 -883 -1.86% $52.76 46,468 30 Jan 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale originated from established 10b5-1 trading plan.